Table 4.
The incidence of deaths, SAEs, and discontinuations due to AEs and SAEs (safety set)
| 13.3 mg/24 h rivastigmine patch N = 355 n (%) | 4.6 mg/24 h rivastigmine patch N = 359 n (%) | |
|---|---|---|
| Deathsa | 1 (0.3) | 1 (0.3) |
| SAE(s) | 53 (14.9) | 49 (13.6) |
| Discontinuations due to SAE(s) | 29 (8.2) | 16 (4.5) |
| Discontinuations due to non‐serious AE(s) | 48 (13.5) | 39 (10.9) |
| Discontinuations due to nausea or vomiting | 9 (2.5) | 4 (1.1) |
| Discontinuations due to skin irritations at the application site | 6 (1.7) | 9 (2.5) |
AE, adverse event; N, number of patients in the population; n, number of patients reporting AE; SAE, serious adverse event.
a
Deaths that occurred during the study period.